[go: up one dir, main page]

ES2182504T3 - Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. - Google Patents

Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.

Info

Publication number
ES2182504T3
ES2182504T3 ES99913138T ES99913138T ES2182504T3 ES 2182504 T3 ES2182504 T3 ES 2182504T3 ES 99913138 T ES99913138 T ES 99913138T ES 99913138 T ES99913138 T ES 99913138T ES 2182504 T3 ES2182504 T3 ES 2182504T3
Authority
ES
Spain
Prior art keywords
formula
physiologically compatible
preparation
compounds
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99913138T
Other languages
English (en)
Inventor
Heinz-Werner Kleemann
Hans-Jochen Lang
Jan-Robert Schwark
Andreas Weichert
Sabine Faber
Hans-Willi Jansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Application granted granted Critical
Publication of ES2182504T3 publication Critical patent/ES2182504T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Bifenilsulfonilcianamidas, procedimiento para su preparación y su utilización como medicamento. **(Fórmula)** Los compuestos de la Fórmula I conformes al invento y sus sales fisiológicamente compatibles se pueden utilizar en un animal, preferiblemente en un mamífero, y en particular en un ser humano como medicamentos por sí solos, en mezclas unos con otros o en forma de formulaciones farmacéuticas. Son objeto del presente invento también los compuestos de la Fórmula I y sus sales fisiológicamente compatibles para su aplicación como medicamentos, su utilización en la terapia y la profilaxis de los cuadros morbosos mencionados y su preparación de medicamentos para estos estados. Además, son objeto del presente invento formulaciones farmacéuticas, que como ingrediente activo contienen una dosis eficaz de por lo menos un compuesto de la Fórmula I y/o de una sal fisiológicamente compatible de éste, junto con sustancias de vehículo y auxiliares usuales, farmacéuticamente irreprochables. Las formulaciones farmacéuticas contienen normalmente de 0, 1 a 99 por ciento en peso, de modo preferido de 0, 5 a 95 por ciento en peso de los compuestos de la Fórmula I y/o de sus sales fisiológicamente compatibles.
ES99913138T 1998-02-04 1999-02-04 Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. Expired - Lifetime ES2182504T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19804251A DE19804251A1 (de) 1998-02-04 1998-02-04 Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Publications (1)

Publication Number Publication Date
ES2182504T3 true ES2182504T3 (es) 2003-03-01

Family

ID=7856542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99913138T Expired - Lifetime ES2182504T3 (es) 1998-02-04 1999-02-04 Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.

Country Status (20)

Country Link
US (1) US6369069B1 (es)
EP (1) EP1053224B1 (es)
JP (1) JP4464559B2 (es)
KR (1) KR100595353B1 (es)
CN (1) CN1231465C (es)
AR (1) AR016448A1 (es)
AT (1) ATE222584T1 (es)
AU (1) AU758154B2 (es)
BR (1) BR9907667A (es)
CA (1) CA2319555A1 (es)
DE (2) DE19804251A1 (es)
DK (1) DK1053224T3 (es)
ES (1) ES2182504T3 (es)
HK (1) HK1034706A1 (es)
HU (1) HU224618B1 (es)
PL (1) PL342453A1 (es)
PT (1) PT1053224E (es)
RU (1) RU2247111C2 (es)
TR (1) TR200002255T2 (es)
WO (1) WO1999040064A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19820064A1 (de) 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
WO2001060818A1 (en) * 2000-02-14 2001-08-23 Tularik Inc. Lxr modulators
EP1305292B1 (de) 2000-07-24 2012-06-20 Bayer CropScience AG Biphenylcarboxamide
CA2474702A1 (en) 2002-01-30 2003-08-07 Tularik Inc Heterocyclic arylsulfonamidobenzylic compounds
DE10206354A1 (de) * 2002-02-14 2003-08-28 Aventis Pharma Gmbh Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
US8841483B2 (en) * 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2062558A1 (en) * 1991-03-08 1992-09-09 Prasun K. Chakravarty Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
JP3290657B2 (ja) * 1991-05-01 2002-06-10 メルク エンド カムパニー インコーポレーテッド アンギオテンシンｉｉ拮抗剤として活性な酸性アラルキルトリアゾール誘導体
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19741635A1 (de) 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Also Published As

Publication number Publication date
JP2002502840A (ja) 2002-01-29
AU3139899A (en) 1999-08-23
CN1289321A (zh) 2001-03-28
US6369069B1 (en) 2002-04-09
WO1999040064A1 (de) 1999-08-12
HK1034706A1 (en) 2001-11-02
AU758154B2 (en) 2003-03-13
JP4464559B2 (ja) 2010-05-19
AR016448A1 (es) 2001-07-04
KR20010040564A (ko) 2001-05-15
DE19804251A1 (de) 1999-08-05
ATE222584T1 (de) 2002-09-15
PL342453A1 (en) 2001-06-04
DK1053224T3 (da) 2002-12-23
CN1231465C (zh) 2005-12-14
HUP0102576A3 (en) 2002-12-28
BR9907667A (pt) 2000-10-24
EP1053224B1 (de) 2002-08-21
HUP0102576A1 (hu) 2002-03-28
PT1053224E (pt) 2002-12-31
KR100595353B1 (ko) 2006-07-03
EP1053224A1 (de) 2000-11-22
HU224618B1 (hu) 2005-11-28
TR200002255T2 (tr) 2001-06-21
CA2319555A1 (en) 1999-08-12
DE59902408D1 (de) 2002-09-26
RU2247111C2 (ru) 2005-02-27

Similar Documents

Publication Publication Date Title
CR9662A (es) Ingrediente farmaceutico canabinoide activo para formas de dosis mejoradas
CY1119148T1 (el) Φαρμακευτικες συνθεσεις και συναφεις μεθοδοι χορηγησης
AR059723A2 (es) Composicion de altas dosis de ibandronato
ES2147294T3 (es) Compuestos terapeuticos.
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
SE9901573D0 (sv) New compounds
UY27553A1 (es) Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno
AR033688A1 (es) Composicion parenteral reconstituible
PA8616201A1 (es) Composiciones farmaceuticas de liberacion sostenida
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
TR200101633T2 (tr) Farmasötik bileşim
ATE257704T1 (de) Pharmazeutische zusammensetzungen enthaltend norastemizol.
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
AU2004224788A1 (en) Use of compounds for the prevention of drug-induced cell toxicity
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
MX9304197A (es) Nuevo uso de dimero de lisozina y composiciones que lo contienen.
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
TR200103144T2 (tr) Yeni bileşikler
KR960700712A (ko) 벤조이미다졸 구충제와 메틸렌디옥시페닐 화합물을 포함하는 상승 화합물(synergistic compositions containing benzimidazole anthelmintics and methylenedioxyphenyl compounds)
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica